Adcetris (Brentuximab Vedotin) is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancers, particularly lymphomas. It combines a monoclonal antibody that specifically targets CD30, a protein expressed on the surface of certain cancer cells, with a potent cytotoxic agent. Adcetris offers a targeted therapeutic approach, reducing harm to healthy cells while effectively killing cancer cells.
Adcetris is a groundbreaking therapy offering hope for patients with relapsed or refractory lymphomas. Its targeted mechanism maximizes efficacy while minimizing off-target toxicity. Proper patient selection, monitoring, and adherence to safety protocols are essential for achieving the best outcomes.
Indications
Adcetris is approved for the treatment of:
- Classical Hodgkin Lymphoma (cHL): After failure of autologous stem cell transplantation (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens.
- Systemic Anaplastic Large Cell Lymphoma (sALCL): In patients with relapsed or refractory disease.
- Peripheral T-cell Lymphomas (PTCL) expressing CD30.
- Cutaneous T-cell Lymphoma (CTCL) expressing CD30.
- Primary Mediastinal Large B-cell Lymphoma (off-label in certain cases as guided by clinical trials).
Adcetris combines an anti-CD30 monoclonal antibody with monomethyl auristatin E (MMAE), a cytotoxic agent. Once the antibody binds to the CD30 protein on cancer cells, the conjugate is internalized, and MMAE is released, disrupting microtubules and inducing cell death.
X
Download App
